Kantonsspital St.Gallen


Stefan Bilz, Sarah Sigrist, Stefan Aczel & Andrea Räss

abstract Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity who have reached target dose during run-in period
project homepage http://www.novonordisk-trials.com/ www.ClinicalTrials.gov
type of project clinical studies
status completed
start of project 2018
end of project 2020
responsible person Dr. med. Stefan Bilz